MedTrace Logo

Cryotherapy Combine Icotinib for Advanced NSCLC Treatment

NCT02744664 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-27

No results posted yet for this study

Summary

This trial is to designed to assess the efficacy and safety of Cryotherapy combine with Icotinib for Advanced NSCLC Patients harboring EGFR mutation.

Conditions

  • Lung Neoplasms

Interventions

PROCEDURE

Cryotherapy

After entering the group subject receive Cryotherapy on lung cancer

DRUG

Icotinib

After Cryotherapy, subjects begin Icotinib administration

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Liu, M.D. · Fuda Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-01
Primary Completion
2017-08-15
Completion
2017-08-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02744664 on ClinicalTrials.gov